TheSpectator

Comments about anything and everything

    Advertisements
  • Categories

  • Archives

test

Posted by Puludad on November 10, 2009

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, has acquired from Gilead Sciences, Inc the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.
Read the rest of this entry »

Advertisements

Posted in Uncategorized | 1 Comment »